ATE445405T1 - Vorbeugung und behandlung von oxidativer-stress- erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen - Google Patents

Vorbeugung und behandlung von oxidativer-stress- erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen

Info

Publication number
ATE445405T1
ATE445405T1 AT02805203T AT02805203T ATE445405T1 AT E445405 T1 ATE445405 T1 AT E445405T1 AT 02805203 T AT02805203 T AT 02805203T AT 02805203 T AT02805203 T AT 02805203T AT E445405 T1 ATE445405 T1 AT E445405T1
Authority
AT
Austria
Prior art keywords
oxidative stress
intracellular levels
glutathione
phase
compounds
Prior art date
Application number
AT02805203T
Other languages
English (en)
Inventor
Xiangqun Gao
Albena Dinkova-Kostova
Paul Talalay
Original Assignee
Brassica Foundation For Chemop
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brassica Foundation For Chemop filed Critical Brassica Foundation For Chemop
Application granted granted Critical
Publication of ATE445405T1 publication Critical patent/ATE445405T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT02805203T 2001-12-18 2002-12-18 Vorbeugung und behandlung von oxidativer-stress- erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen ATE445405T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34027301P 2001-12-18 2001-12-18
PCT/US2002/040457 WO2003051313A2 (en) 2001-12-18 2002-12-18 Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes

Publications (1)

Publication Number Publication Date
ATE445405T1 true ATE445405T1 (de) 2009-10-15

Family

ID=23332637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02805203T ATE445405T1 (de) 2001-12-18 2002-12-18 Vorbeugung und behandlung von oxidativer-stress- erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen

Country Status (9)

Country Link
US (3) US7407986B2 (de)
EP (3) EP2138170A3 (de)
JP (1) JP2005536449A (de)
CN (1) CN1620304B (de)
AT (1) ATE445405T1 (de)
AU (1) AU2002357311A1 (de)
CA (1) CA2470583C (de)
DE (1) DE60234052D1 (de)
WO (1) WO2003051313A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015913A (en) 1996-09-06 2000-01-18 Mars, Incorporated Method for producing fat and/or solids from cocoa beans
DE60234052D1 (de) * 2001-12-18 2009-11-26 Brassica Foundation For Chemop Vorbeugung und behandlung von oxidativer-stress-erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen
DE602004005617T2 (de) * 2003-12-22 2007-12-13 Alcon Inc. Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie
MXPA06006862A (es) * 2003-12-22 2007-01-26 Alcon Inc Agentes para el tratamiento de la retinopatia diabetica y formacion de drusen en degeneracion macular.
JP5133064B2 (ja) * 2005-01-05 2013-01-30 國防教育研究基金会 ウリジン２リン酸（ｕｄｐ）−グルクロン酸転移酵素２ｂ（ｕｇｔ２ｂ）の抑制剤及び促進剤
US7744937B2 (en) * 2005-08-09 2010-06-29 Kraft Foods Global Brands Llc Chemoprotectants from crucifer seeds and sprouts
WO2008016095A1 (en) * 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT
JP2008247898A (ja) * 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US20080311276A1 (en) * 2007-06-12 2008-12-18 Kraft Foods Holdings, Inc. Production of Glucosinolates from Agricultural By-Products & Waste
US20080311192A1 (en) * 2007-06-12 2008-12-18 Kraft Foods Holdings, Inc. Enteric-Coated Glucosinolates And Beta-Thioglucosidases
BRPI0911874A2 (pt) * 2008-04-29 2018-05-22 Pharnext composições combinadas para o tratamento da doença de alzheimer e doenças relacionadas com zonisamida e acamprosato
US20090324522A1 (en) * 2008-06-18 2009-12-31 Western Holdings, Llc Skin protectant compositions
WO2010005533A2 (en) * 2008-06-30 2010-01-14 The Johns Hopkins University Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa
GB0811992D0 (en) * 2008-07-01 2008-08-06 Mithen Richard Treatment
WO2010084661A1 (ja) * 2009-01-23 2010-07-29 金印株式会社 イソチオシアネート類含有組成物、食品、食品素材、医薬品、化粧品および日用品雑貨類
EP2616061A4 (de) * 2010-09-17 2014-03-12 Brassica Prot Products Llc Formulierungen zur behandlung mit glucosinolat
US10273205B2 (en) 2011-01-03 2019-04-30 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms
US11407713B2 (en) 2011-01-03 2022-08-09 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US8933119B2 (en) 2011-01-03 2015-01-13 The William M. Yarbrough Foundation Method for treating phytophotodermatitis
US10647668B2 (en) 2011-01-03 2020-05-12 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US9962361B2 (en) 2011-01-03 2018-05-08 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US11279674B2 (en) 2011-01-03 2022-03-22 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US10308599B2 (en) 2011-01-03 2019-06-04 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
US8865765B2 (en) 2011-01-12 2014-10-21 The William M. Yarbrough Foundation Method for treating eczema
US9532969B2 (en) 2011-02-08 2017-01-03 The William M. Yarbrough Foundation Method for treating psoriasis
EP2678029B1 (de) 2011-02-22 2016-11-09 Caudill Seed Company, Inc. Sprühgetrocknete myrosinase und verwendung zur herstellung von isothiocyanaten
EP2601946A1 (de) 2011-12-06 2013-06-12 Pécsi Tudomànyegyetem Behandlung und Prävention von Erkrankungen in Beziehung mit oxidativer Belastung
EP2859890A3 (de) * 2011-10-31 2015-08-05 The Johns Hopkins University Verfahren und Zusammensetzungen zur Behandlung von Autismus
US10080734B2 (en) 2012-07-26 2018-09-25 The William M. Yarbrough Foundation Method for treating autism and other neurodevelopmental disorders
US10335387B2 (en) 2012-07-26 2019-07-02 The William M. Yarbrough Foundation Method for treating infectious diseases with isothiocyanate functional compounds
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
WO2014018874A1 (en) 2012-07-26 2014-01-30 The William M. Yarbrough Foundation Method for treating skin cancer
US9839621B2 (en) 2012-07-26 2017-12-12 The William M. Yarbrough Foundation Method for treating bladder cancer
US9949943B2 (en) 2012-07-26 2018-04-24 The William M. Yarbrough Foundation Method for treating neurodegenerative diseases
US10434081B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Inhibitors of macrophage migration inhibitory factor
US10434082B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
ITMI20121774A1 (it) * 2012-10-19 2014-04-20 Placido Bramanti Uso di un fitochimico bioattivato come agente neuroprotettivo per la prevenzione ed il trattamento di patologie correlate al sistema nervoso
CA2925546C (en) 2012-10-29 2022-06-14 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
US20150328337A1 (en) * 2012-12-19 2015-11-19 The Johns Hopkins University Protection from oxidative damage by gene transfer by glutamate cysteine ligase and glutathione synthase
WO2015002279A1 (ja) * 2013-07-03 2015-01-08 味の素株式会社 グルタチオン生成促進用組成物
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
EP3541401A4 (de) 2016-11-17 2020-07-29 Renovion, Inc. Behandlung von atemwegserkrankungen und -infektionen mit glutathionzusammensetzungen
ES3008699T3 (en) 2017-11-17 2025-03-24 Renovion Inc Stable ascorbic acid compositions and methods of using the same
US10441578B2 (en) 2018-01-19 2019-10-15 Louis Habash Altering expression level of glutathione S-transferase genes by treating a human subject with a nitroxide
AU2023205178B2 (en) 2022-01-04 2025-09-25 Renovion, Inc. Aqueous solution comprising a glutathione salt
CN120187671A (zh) * 2022-08-30 2025-06-20 肖恩·J·格林 用于改善口内、鼻和/或鼻咽区域中一氧化氮水平的组合物及方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36784A (en) 1862-10-28 Improvement in separators and smut-mach ines
US5747459A (en) * 1991-02-04 1998-05-05 Nestec, Ltd. Method for insuring adequate intracellular glutathione in tissue
IT1256178B (it) * 1992-11-30 1995-11-29 Lorenzo Ferrari Composti ad attivita' terapeutica utili per il trattamento di malattieconnesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
US5411986A (en) 1993-03-12 1995-05-02 The Johns Hopkins University Chemoprotective isothiocyanates
AU7596994A (en) 1993-11-01 1995-05-18 Free Radical Sciences, Inc. Methods and compositions for retarding the aging process
FR2723588B1 (fr) * 1994-08-12 1996-09-20 Rhone Poulenc Rorer Sa Adenovirus comprenant un gene codant pour la glutathion peroxydase
CA2276183C (en) 1996-12-31 2009-06-09 Antioxidant Pharmaceuticals Corporation Pharmaceutical preparations of glutathione and methods of administration thereof
US6270780B1 (en) * 1997-07-25 2001-08-07 Chesebrough-Pond's Usa Co., Division Of Conopco Cosmetic compositions containing resveratrol
JPH11124311A (ja) * 1997-10-20 1999-05-11 Shiseido Co Ltd 光毒性抑制剤
DK1063981T3 (da) * 1998-03-16 2002-10-14 Somerset Pharmaceuticals Inc Anvendelse af selegilin eller desmethylselegilin til behandling af sår, brandsår og dermatologiske skader
CA2239205A1 (en) * 1998-05-29 1999-11-29 Gabrielle Boulianne Extension of lifespan by overexpression of a gene that increases reactive oxygen metabolism
JP3899210B2 (ja) * 1999-08-27 2007-03-28 金印株式会社 グルタチオン−ｓ−トランスフエラーゼの活性誘導物質およびこれを含む食品
AU1784301A (en) * 1999-11-24 2001-06-04 Alticor Inc. Topical skin composition
AU5440901A (en) 1999-12-20 2001-07-03 Cognis France, S.A. Cosmetic and/or pharmaceutical preparations
JP2001316262A (ja) * 2000-02-29 2001-11-13 Santen Pharmaceut Co Ltd 抗酸化剤
CA2408152A1 (en) * 2000-05-05 2001-11-15 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
US6495170B1 (en) 2000-08-16 2002-12-17 N. V. Nutricia Method of increasing the presence of glutathione in cells
US6737441B2 (en) * 2000-08-21 2004-05-18 Jed W. Fahey Treatment of helicobacter with isothiocyanates
DE60234052D1 (de) * 2001-12-18 2009-11-26 Brassica Foundation For Chemop Vorbeugung und behandlung von oxidativer-stress-erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen
EP1890683B1 (de) * 2005-04-29 2011-06-08 Johns Hopkins University Verfahren zur unterdrückung von durch uv-licht induzierter hautcarcinogenese

Also Published As

Publication number Publication date
US8709406B2 (en) 2014-04-29
CN1620304A (zh) 2005-05-25
CA2470583A1 (en) 2003-06-26
EP1474158A4 (de) 2006-09-13
CN1620304B (zh) 2010-06-23
EP2698153A1 (de) 2014-02-19
EP2138170A3 (de) 2010-06-23
US7407986B2 (en) 2008-08-05
CA2470583C (en) 2011-03-15
WO2003051313A3 (en) 2003-10-16
EP1474158B1 (de) 2009-10-14
US8303949B2 (en) 2012-11-06
EP1474158A2 (de) 2004-11-10
WO2003051313A2 (en) 2003-06-26
DE60234052D1 (de) 2009-11-26
US20090017002A1 (en) 2009-01-15
EP2138170A2 (de) 2009-12-30
US20130157965A1 (en) 2013-06-20
AU2002357311A1 (en) 2003-06-30
JP2005536449A (ja) 2005-12-02
US20050063965A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
ATE445405T1 (de) Vorbeugung und behandlung von oxidativer-stress- erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen
DE59907752D1 (de) Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien
DE60119784D1 (de) Cyclische salen metall verbindungen als einfänger von sauerstoffradikalen und verwendbar als antioxidantien bei der behandlung und vorbeugung von krankheiten
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE495755T1 (de) Vorbeugung und behandlung von amyloidogenischen krankheiten
EA200501023A1 (ru) Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида
EA200200847A1 (ru) Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
ATE179888T1 (de) Ophthalmische zubereitung zur behandlung oder prävention von trockenem auge und krankheiten, die dadurch verursacht werden, enthaltend 12- sulfodehydroabietsäure
DE60203847D1 (de) Verbindungen enthaltend S-Tofisopam sowie Verwendung dieser Verbindungen zur Herstellung eines Medikamentes zur Behandlung oder Prophylaxe von Krämpfen und Anfällen
DE69819110D1 (de) Ein Arzneimittel zur Behandlung von Fettleibigkeit und Verbesserung des lipidmetabolismus
DE60030732D1 (de) Verwendung von 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol zur prävention oder behandlung viraler myocarditis
ATE409028T1 (de) Arzneien zur behandlung von nervenerkrankungen
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
WO2002100836A8 (en) Compounds, compositions and methods for modulating beta-amyloid production
ATE410172T1 (de) Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes
DE60138385D1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
ATE425967T1 (de) Piperazin und piperadin-derivate fur die behandlung von neurologischen krankheiten
DE69926794D1 (de) Ponazuril zur behandlung von durch coccidia neurologischen und "abortigenic" verursachten erkrankungen
ATE235237T1 (de) Sertralin zur behandlung von post-myocard-infarkt-patienten
ATE193206T1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
ATE428436T1 (de) Mittel zur behandlung oder prävention allergischer erkrankungen mit bearbeitetem erdnusssamen-überzug
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
EP1693060A4 (de) Mittel zur behandlung oder prävention von ischämischer neuropathie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties